Despite the clinical success of BCR::ABL1 tyrosine kinase inhibitors (TKIs) therapy for treatment of chronic myeloid leukemia (CML), a substantial number of patients will experience resistance to this pharmacological approach and relapse due to BCR::ABL1-dependent or independent mechanisms [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.